|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Role of transcatheter arterial embolization for massive bleeding from gastroduodenal ulcers显示文摘Intractable bleeding from gastric and duodenal ulcers is associated with significant morbidity and mortality. Aggressive treatment with early endoscopic hemostasis is essential for a favourable outcome. In as many as 12%-17% of patients,endoscopy is either not available or unsuccessful. Endovascular therapy with selective catheterization of the culprit vessel and injection of embolic material has emerged as an alternative to emergent operative intervention in high-risk patients. There has not been a systematic literature review to assess the role for embolotherapy in the treatment of acute upper gastrointestinal bleeding from gastroduo-denal ulcers after failed endoscopic hemostasis. Here,we present an overview of indications,techniques,and clinical outcomes after endovascular embolization of acute peptic-ulcer bleeding. Topics of particular relevance to technical and clinical success are also discussed. Our review shows that transcatheter arterial embolization is a safe alternative to surgery for massive gastroduodenal bleeding that is refractory to endoscopic treatment,can be performed with high technical and clinical success rates,and should be considered the salvage treatment of choice in patients at high surgical risk. | Romaric Loffroy Boris Guiu | 2009 | World Journal of Gastroenterology2009，15，47： | 27 |
| 2 | Liver venous deprivation versus portal vein embolization before major hepatectomy:future liver remnant volumetric and functional changes显示文摘Background:We previously showed that embolization of portal inflow and hepatic vein(HV)outflow(liver venous deprivation,LVD)promotes future liver remnant(FLR)volume(FLR-V)and function(FLR-F)gain.Here,we compared FLR-V and FLR-F changes after portal vein embolization(PVE)and LVD.Methods:This study included all patients referred for liver preparation before major hepatectomy over 26 months.Exclusion criteria were:unavailable baseline/follow-up imaging,cirrhosis,Klatskin tumor,two-stage hepatectomy.99mTc-mebrofenin SPECT-CT was performed at baseline and at day 7,14 and 21 after PVE or LVD.FLR-V and FLR-F variations were compared using multivariate generalized linear mixed models(joint modelling)with/without missing data imputation.Results:Baseline FLR-F was lower in the LVD(n=29)than PVE group(n=22)(P<0.001).Technical success was 100%in both groups without any major complication.Changes in FLR-V at day 14 and 21(+14.2%vs.+50%,P=0.002;and+18.6%vs.+52.6%,P=0.001),and in FLR-F at day 7,14 and 21(+23.1%vs.+54.3%,P=0.02;+17.6%vs.+56.1%,P=0.006;and+29.8%vs.+63.9%,P<0.001)differed between PVE and LVD group.LVD(P=0.009),age(P=0.027)and baseline FLR-V(P=0.001)independently predicted FLR-V variations,whereas only LVD(P=0.01)predicted FLR-F changes.After missing data handling,LVD remained an independent predictor of FLR-V and FLR-F variations.Conclusions:LVD is safe and provides greater FLR-V and FLR-F increase than PVE.These results are now evaluated in the HYPERLIV-01 multicenter randomized trial. | Boris Guiu François Quenet Fabrizio Panaro Lauranne Piron Christophe Cassinotto Astrid Herrerro François-Régis Souche Margaux Hermida Marie-Ange Pierredon-Foulongne Ali Belgour Serge Aho-Glele Emmanuel Deshayes | 2020 | Hepatobiliary Surgery and Nutrition2020，9，5： | 10 |
| 3 | Hepatic arterial infusion of gemcitabine-oxaliplatin in a large metastasis from colon cancer显示文摘Hepatic arterial infusion (HAI) of chemotherapy can be performed in cases of liver-confined metastatic disease,resulting in increased local drug concentrations.Here we report the case of a 61-year-old man who presented with an isolated large unresectable liver metastasis of colon cancer after failure of surgery and multiple administration of systemic chemotherapy.The patient was treated with a combination of gemcitabine and oxaliplatin using HAI.The tolerance was excellent and a radiological complete response was obtained after 8 cycles of HAI.The rationale for the use of gemcitabine and oxaliplatin as well as that for the combination of the 2 drugs is discussed in this paper.HAI of gemcitabine-oxaliplatin should be evaluated in further clinical trials. | Boris Guiu Julie Vincent Séverine Guiu Sylvain Ladoire Pablo Ortega-Deballon Jean-Pierre Cercueil Bruno Chauffert Franois Ghiringhelli | 2010 | World Journal of Gastroenterology2010，16，9： | 4 |
| 4 | Optimization of the future remnant liver:review of the current strategies in Europe显示文摘Liver resection still represent the treatment of choice for liver malignancies,but in some cases inadequate future remnant liver(FRL)can lead to post hepatectomy liver failure(PHLF)that still represents the most common cause of death after hepatectomy.Several strategies in recent era have been developed in order to generate a compensatory hypertrophy of the FRL,reducing the risk of post hepatectomy liver failure.Portal vein embolization,portal vein ligation,and ALLPS are the most popular techniques historically adopted up to now.The liver venous deprivation and the radio-embolization are the most recent promising techniques.Despite even more precise tools to calculate the relationship among volume and function,such as scintigraphy with^(99m)Tc-mebrofenin(HBS),no consensus is still available to define which of the above mentioned augmentation strategy is more adequate in terms of kind of surgery,complexity of the pathology and quality of liver parenchyma.The aim of this article is to analyse these different strategies to achieve sufficient FRL. | Riccardo Memeo Maria Conticchio Emmanuel Deshayes Silvio Nadalin Astrid Herrero Boris Guiu Fabrizio Panaro | 2021 | Hepatobiliary Surgery and Nutrition2021，10，3： | 4 |
| 5 | Transcatheter Arterial Embolization of Splenic Artery Aneurysms and Pseudoaneurysms: Short- and Long-Term Results显示文摘 | Romaric Loffroy Boris Guiu Jean-Pierre Cercueil C?me Lepage Nicolas Cheynel Eric Steinmetz Frédéric Ricolfi Denis Krausé | 2008 | Annals of Vascular Surgery2008，，5： | 2 |
| 6 | Sirolimus,bevacizumab,5-Fluorouracil and irinotecan for advanced colorectal cancer:A pilot study显示文摘AIM:To evaluate the efficacy and the safety of combined 5-Fluorouracil,irinotecan,bevacizumab and sirolimus in refractory advanced colorectal carcinoma. METHODS:We initiated a regimen with at day 1 an injection(iv)of bevacizumab at 5 mg/kg,followed by 180 mg/m 2 irinotecan,followed by Leucovorin 400 mg/m 2 ,followed by a 5-Fluorouracil bolus 400 mg/m 2 and a 46-h infusion 2400 mg/m 2 .Sirolimus was given orally as continuous administration of 2 mg twice a day every days.This treatment was repeated every 14 d. RESULTS:A total of 12 patients were enrolled. All patients presented with metastatic disease that had failed at least three lines of chemotherapy that contained oxaliplatin,irinotecan and bevacizumab. Cetuximab failure was also observed in all K-Ras wildtype patients.The median number of cycles was 8.5 (range 2-20)and clinical benefit was observed in eight patients.The median time to progression was 5 mo and the median survival was 8 mo.Grade 3 neutropenia developed in four patients,and grade 3 diarrhea and stomatitis in two. CONCLUSION:The combination regimen of 5-Fluorouracil,irinotecan,bevacizumab and sirolimus in advanced colorectal carcinoma after failure of classical treatment is feasible and promising.Further evaluation of this combination is required. | Francois Ghiringhelli Boris Guiu Bruno Chauffert Sylvain Ladoire | 2009 | World Journal of Gastroenterology2009，15，34： | 2 |
| 7 | Role of transcatheter arterial embolization for massive bleeding from gastroduodenal ulcers 显示文摘 | Romaric Loffroy Boris Guiu | 2012 | World Journal of Gastroenterology2012，7，3： | 1 |
| 8 | Raltitrexed and oxaliplatin hepatic arterial infusion for advanced colorectal cancer: a retrospective study显示文摘 | Cedric Khouri Boris Guiu Jean Pierre Cercueil Bruno Chauffert Sylvain Ladoire Francois Ghiringhelli | 2010 | Anti-Cancer Drugs2010，，6： | 1 |
| 9 | Constitutive androstane receptor activation stimulates faecal bile acid excretion and reverse cholesterol transport in mice显示文摘 | Anne Laure Sberna Mahfoud Assem Thomas Gautier Jacques Grober Boris Guiu Aline Jeannin Jean-Paul Pais de Barros Anne Athias Laurent Lagrost David Masson | 2010 | Journal of Hepatology2010，，1： | 1 |
| 10 | Arterial Embolotherapy for Endoscopically Unmanageable Acute Gastroduodenal Hemorrhage: Predictors of Early Rebleeding显示文摘 | Romaric Loffroy Boris Guiu Philippe D'Athis Lise Mezzetta Alice Gagnaire Jean–Louis Jouve Pablo Ortega–Deballon Nicolas Cheynel Jean–Pierre Cercueil Denis Krausé | 2009 | Clinical Gastroenterology and Hepatology2009，，5： | 1 |
| 11 | Simultaneous Biliary Drainage and Portal Vein Embolization Before Extended Hepatectomy for Hilar Cholangiocarcinoma: Preliminary Experience显示文摘 | Boris Guiu Pierre Bize Nicolas Demartines Micka?l Lesurtel Alban Denys | 2014 | CardioVascular and Interventional Radiology2014，，3： | 1 |
| 12 | Role of transcatheter arterial emboliza- tion for massive bleeding from gastroduodenal ulcers显示文摘 | Romaric Loffroy Boris Guiu | 2012 | World Jour- nal of Gastroenterology2012，7，3： | 1 |
| 13 | Mapping of liver fat with triple-echo gradient echo imaging: validation against 3.0-T proton MR spectroscopy显示文摘 | Boris Guiu Romaric Loffroy Jean-Michel Petit Serge Aho Douraied Ben Salem David Masson Patrick Hillon Jean-Pierre Cercueil Denis Krause | 2009 | European Radiology2009，，7： | 1 |
| 14 | Magnetic resonance imaging and spectroscopy for quantification of hepatic steatosis: Urgent need for standardization!显示文摘 | Boris Guiu | 2009 | Journal of Hepatology2009，，6： | 1 |
| 15 | Intravoxel Incoherent Motion Diffusion-weighted Imaging in Nonalcoholic Fatty Liver Disease: A 3.0-T MR Study显示文摘 | Boris Guiu Jean-Michel Petit Violaine Capitan Serge Aho David Masson Pierre-Henri Lefevre Sylvain Favelier Romaric Loffroy Bruno Vergès Patrick Hillon Denis Krausé Jean-Pierre Cercueil | 2012 | Radiology2012，，1： | 1 |
| 16 | Arterial embolization is the best treatment for pancreaticojejunal anastomotic bleeding after pancreatoduodenectomy显示文摘Massive pancreaticojejunal anastomotic bleeding, mainly from the gastroduodenal stump, is one of the most common complications of pancreato-duodenectomy. Selective angiography should be systematically the first step of investigative procedure in such situations. Pharmacoarteriography may be used if the bleeding point is not spontaneously identified, and allows safe and effective treatment with transcatheter arterial embolization compared to blind open surgical hemostasis. Coil embolization of the common or proper hepatic artery on either side of the bleeding point with 'sandwich technique' is then the preferred technique to prevent retrograde filling. Surgery should be performed only as a last resort. | Romaric Loffroy Boris Guiu | 2009 | World Journal of Gastroenterology2009，15，32： | 1 |
| 17 | Raltitrexed and oxaliplatin hepatic arterial infusion for advanced colorectal cancer: a retrospective study显示文摘 | Cedric Khouri Boris Guiu Jean Pierre Cercueil Bruno Chauffert Sylvain Ladoire Francois Ghiringhelli | 2010 | Anti-Cancer Drugs2010，，6： | 1 |
| 18 | Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: Lipiodol vs . drug-eluting beads显示文摘 | Boris Guiu Frédéric Deschamps Serge Aho Flore Munck Clarisse Dromain Valérie Boige David Malka Sophie Leboulleux Michel Ducreux Martin Schlumberger Eric Baudin Thierry de Baere | 2011 | Journal of Hepatology2011，，3： | 1 |
| 19 | Large,multifocal or portal vein-invading hepatocellular carcinoma(HCC)downstaged by Y90 using personalized dosimetry:safety,pathological results and outcomes after surgery显示文摘Background:Transarterial radioembolization(TARE)has recently been recognized as a bridging/downstaging therapy to surgery for early hepatocellular carcinomas(HCCs)with high rates of complete pathological necrosis(CPN)on liver explants.In patients with portal vein tumoral thrombus(PVTT),multifocal or large tumors,TARE has mainly a palliative role and surgery remains controversial in this poor-prognosis population.Personalized dosimetry recently proved to outperform standard dosimetry used in prior negative Y90 randomized-controlled trials.Methods:In this retrospective study,we evaluated safety,radiological and pathological response and outcomes in HCC patients with PVTT,multifocal or large tumors,who underwent surgery after downstaging using TARE with Y90-loaded glass microspheres with personalized dosimetry.Results:Between December 2015 and October 2021,18 unresectable patients(14/18 with PVTT)had surgery(16 resections,2 liver transplantations)6.2 months(range,2-14.6 months)after a single Y90 treatment.No 90-day mortality was reported.Objective modified response criteria in solid tumors(mRECIST)response were noted in all but one patient.Complete and extensive(50-99%)necrosis was observed in 36%and 45%of tumors,respectively.The post-treatment tumor-absorbed dose significantly differed depending on the extent of pathological necrosis(P=0.045).Median overall survival and progression-free survival(PFS)were respectively of 61.8 months[95%CI:31.4 months-not reached(NR)]and 49.3 months(95%CI:14 months-NR).PFS was longer in patients with complete imaging response[median NR(none recurred or died)vs.21.5 months(95%CI:10.1 months-NR),P<0.001]and in those with complete pathological response[median NR vs.22.5 months(95%CI:10.1 months-NR),P<0.001].Conclusions:Y90 TARE using personalized dosimetry can provide high rates of imaging and pathological response in patients with PVTT,large or multifocal HCC.Subsequent surgery is safe and leads to outcomes far exceeding expectations in an otherwise poor prognosis population with no chance for cure. | Mohamad Azhar Meerun Carole Allimant Benjamin Rivière Astrid Herrero Fabrizio Panaro Eric Assenat Christophe Cassinotto Denis Mariano-Goulart Boris Guiu | 2023 | Hepatobiliary Surgery and Nutrition2023，12，3： | 0 |
| 20 | Hepatocellular carcinoma chemoprevention in chronic hepatitis B patients:all-in on statins?显示文摘Chronic hepatitis B(CHB)affects approximately 257 million individuals worldwide,the highest prevalence being in Western Pacific WHO Region[6.2%(1)].In highly endemic CHB regions,the 5-year cumulative incidence of hepatocellular carcinoma(HCC)ranges from 3%to 17%,depending on the presence of cirrhosis(2).Antiviral treatment decreases the risk of HCC,without abolishing it completely(3).Paradoxically,by decreasing liver-related mortality,antiviral treatment in CHB patients causes an increase in HCC long-term incidence(4). | JoséUrsic-Bedoya Boris Guiu | 2020 | Hepatobiliary Surgery and Nutrition2020，9，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员